These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 26169964)
1. Next Generation of Preclinical Liver Cancer Models. Weber A; O'Connor T; Heikenwalder M Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964 [TBL] [Abstract][Full Text] [Related]
2. The role of sorafenib in hepatocellular carcinoma. Gholam P Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581 [No Abstract] [Full Text] [Related]
3. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib. Groß C; Steiger K; Sayyed S; Heid I; Feuchtinger A; Walch A; Heß J; Unger K; Zitzelsberger H; Settles M; Schlitter AM; Dworniczak J; Altomonte J; Ebert O; Schwaiger M; Rummeny E; Steingötter A; Esposito I; Braren R Clin Cancer Res; 2015 Oct; 21(19):4440-50. PubMed ID: 25995341 [TBL] [Abstract][Full Text] [Related]
7. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071 [TBL] [Abstract][Full Text] [Related]
8. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. Weintraub JL; Salem R J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168 [TBL] [Abstract][Full Text] [Related]
10. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604 [TBL] [Abstract][Full Text] [Related]
11. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gish RG; Finn RS; Marrero JA Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427 [TBL] [Abstract][Full Text] [Related]
12. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
14. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514 [TBL] [Abstract][Full Text] [Related]
18. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036 [TBL] [Abstract][Full Text] [Related]
19. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib: 10 years after the first pivotal trial. Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]